Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1

Blood

Volumn 111, Issue 6, 2008, Pages 3131-3136

  Shin, Dong Hoon ^a   Chun, Yang Sook ^b   Lee, Dong Soon ^a   Huang, L Eric ^c   Park, Jong Wan ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ERYTHROPOIETIN; FACTOR INHIBITING HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEASOME INHIBITOR; PROTEIN P300; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; BORONIC ACID DERIVATIVE; CITED2 PROTEIN, HUMAN; DNA BINDING PROTEIN; HIF1AN PROTEIN, HUMAN; HISTONE ACETYLTRANSFERASE PCAF; HYPOXIA INDUCIBLE FACTOR 1; PYRAZINE DERIVATIVE; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ARTICLE; CELL DEATH; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPOXIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; TWO HYBRID SYSTEM; ADAPTATION; CELL HYPOXIA; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASM;

ADAPTATION, BIOLOGICAL; BORONIC ACIDS; CELL HYPOXIA; CELL LINE; DNA-BINDING PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; P300-CBP TRANSCRIPTION FACTORS; PYRAZINES; REPRESSOR PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 42449130564     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-120576     Document Type: Article

References (33)

1. Hockel M. Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-276.
2. Pouyssegur J. Dayan F. Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437-443.
3. Asosingh K. De Raeve H, de Ridder M, et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica. 2005;90:810-817.
4. KeQ. Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006;70:1469-1480.
5. Wang GL. Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Bio1 Chem. 1995;270:1230-1237.
6. Jaakkola P. Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
7. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292:464-468.
8. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001;20:5197-5206.
9. BruicK RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337-1340.
10. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43-54.
11. Mahon PC, Hirota K, Semenza GL. FiH-1: a novel protein that interacts with HIF-1alpha and VHLto mediate repression of HlF-1 transcriptional activity. Genes Dev. 2001; 15;2675-2686.
12. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002;16:1466-1471.
13. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006;57:33-47.
14. Hideshima T Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
15. Roccaro AM, HideshimaT, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66:184-191.
16. Brignole C, Marimpietri D, Pastorino F, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst. 2006;98:1142-1157.
17. Mackay H, Hedley D, Major P, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res. 2005;11:5526-5533.
18. Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1 alpha C-terminaI activation domain. Mol Cell Biol. 2006;26:5895-5907.
19. Birle DC, Hedley DW. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res. 2007;67:1735-1743.
20. Chun YS, Choi E, Kim TY, Kim MS, Park JW. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem J. 2002;362:71-79.
21. Yeo EJ, Ryu JH, ChoYS, et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood. 2006:107:916-923.
22. Gu J, Milligan J, Huang LE. Molecular mechanism of hypoxia-inducible factor 1 alpha-p300 interaction. A Ieucine-rich interface regulated by a single cysteine. J Biol Chem. 2001;276:3550-3554.
23. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, Livingston DM. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev. 1999;13:64-75.
24. Freedman SJ, Sun ZY, Kung AL, France DS, Wagner G, Eck MJ. Structural basis for negative regulation of hypoxia-inducible factor-1 alpha by CITED2. Nat Struct Biol. 2003;10:504-512.
25. Shin DH. Li SH, Chun YS, Huang LE, Kim MS, Park JW. CITED2 mediates the paradoxical responses of HIF-1 alpha to proteasome inhibition. Oncogene. Prepublished October 1, 2007 as DOl 10.1038/sj.onc.1210826.
26. Zheng X, Ruas JL, Cao R, et al. Cell-type-specific regulation of degradation of hypoxia-inducible factor 1 alpha: role of subcellular compartmentalization. Mol Cell Biol. 2006;26:4628-4641.
27. Rajkumar SV, Richardson PG, HideshimaT, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23:630-639.
28. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor lalpha by the ubiquitinproteasome pathway. J Biol Chem. 1999;274: 6519-6525.
29. Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1alpha. J Cell Sci. 1999;112:1203-1212.
30. Hagg M, Wennstrom S. Activation of hypoxiainduced transcription in normoxia. Exp Cell Res. 2005;306:180-191.
31. Dann CE 3rd Bruick RK, Deisenhofer J. Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc Natl Acad Sci U S A. 2002;99:15351-15356.
32. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nature Rev Cancer. 20022;38-47.
33. Yeo EJ, Chun YS, Park JW. New anticancer strategies targeting HIF-1. Biochem Pharmacol. 2004; 68:1061-1069.